J Dig Cancer Res.  2019 Jun;7(1):22-25. 10.0000/jdcr.2019.7.1.22.

Extraordinary Response of Metastatic Pancreatic Cancer to Chemotherapy

• Shin DW
• Kim J
• Lee JC
• Kim J
• Hwang JH

• KMID: 2455391
• DOI: http://doi.org/10.0000/jdcr.2019.7.1.22

Abstract

A 58-year-old woman presented with right flank and back pain for one month. After undergoing an abdominal computed tomography (CT), she was referred to our hospital. The abdominal CT showed a hypodense pancreatic tail mass with multiple retroperitoneal lymph node metastases. Positron emission tomography-computed tomography (PET-CT) scan showed high 18F-FDG uptake in pancreatic tumor and enlarged lymph nodes. Endoscopic ultrasound fine needle aspiration (EUS-FNA) revealed adenocarcinoma, which stained strongly in hENT1 (human equilibrative nucleoside transporter 1) on immunohistochemistry. She received gemcitabine 1,000 mg/m²+ nanoparticle albumin-bound paclitaxel 125 mg/m² as a palliative chemotherapy. Follow-up abdominal CT and PET-CT after 4 cycles of chemotherapy showed that both pancreatic mass and the metastatic retroperitoneal lymph nodes were nearly disappeared. We report a case of 58-year-old female with metastatic pancreatic cancer who had a dramatic response to palliative chemotherapy (gemcitabine plus nanoparticle albumin-bound paclitaxel).

Keyword

Metastatic pancreatic cancer; Gemcitabine; Nanoparticle albumin-bound paclitaxel; hENT1 immunohistochemical stain

MeSH Terms

Adenocarcinoma
Albumin-Bound Paclitaxel
Back Pain
Biopsy, Fine-Needle
Drug Therapy*
Electrons
Female
Fluorodeoxyglucose F18
Follow-Up Studies
Humans
Immunohistochemistry
Lymph Nodes
Middle Aged
Nanoparticles
Neoplasm Metastasis
Nucleoside Transport Proteins
Pancreatic Neoplasms*
Tail
Tomography, X-Ray Computed
Ultrasonography
Albumin-Bound Paclitaxel
Fluorodeoxyglucose F18
Nucleoside Transport Proteins